arl_stat
☆    

India,
2018-07-13 13:26

Posting: # 19046
Views: 1,399
 

 Multiple Dose, Steady State-Partial reference replicate [Design Issues]

Greetings to all.

Please help in understanding whether it is possible to conduct “An open-label, randomized, Multiple Dose, Steady State, two treatments, three periods, three sequence, three way, Reference Replicated crossover bioequivalence study” for USFDA Submission?

Kindly share any reference article if any.

Thank you !!!


Edit: Category changed; see also this post #1[Helmut]
ElMaestro
★★★

Denmark,
2018-07-13 13:42

@ arl_stat
Posting: # 19047
Views: 1,251
 

 Multiple Dose, Steady State-Partial reference replicate

Hi arl_stat,

» Please help in understanding whether it is possible to conduct “An open-label, randomized, Multiple Dose, Steady State, two treatments, three periods, three sequence, three way, Reference Replicated crossover bioequivalence study” for USFDA Submission?

Yes to everything except (conditionally) the term 'three way' in the context of your post.

if (3) 4

x=c("Foo", "Bar")
b=data.frame(x)
typeof(b[,1]) ##aha, integer?
b[,1]+1 ##then let me add 1


Best regards,
ElMaestro

“(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures.” New York Times (ed.), June 9, 2018.
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2018-07-13 14:35

@ arl_stat
Posting: # 19049
Views: 1,260
 

 Logistic nigthmare

Hi arl_stat,

I hope you don’t regularly start with the title of a study and then think about the design. I suggest to do it the other way ’round. ;-)

There are tons of posts in the forum discussing why the partial replicate (TRR|RTR|RRT) is a lousy design. One may fail to get a result if reference-scaling is not applicable (swR <0.294) with the FDA’s SAS-code for ABE (no convergence of the – over-specified – mixed-effects model). Please forget this design! Use one of the fully replicated designs instead (four periods: TRTR|RTRT, TRRT|RTTR, or TTRR|RRTT; three periods: TRT|RTR or TRR|RTT).

Combining replicates with multiple doses is very, very tricky. In a naïve way one can think about adding n saturation / switch-over administrations and get for the TRT|RTR this:

[n×T] TRT [n×R] RTR
[n×R] RTR [n×T] TRT

But wait a minute! The comparisons require that we are in (pseudo) steady state. That would be valid only if the true T/R-ratio is exactly one. Otherwise only the estimates in the first period are correct (since we have n administrations of the respective treatment before) but estimates in the other periods will be biased. You have to guarantee that you are in steady state for each administration. Then you end up with this:

[n×T] T [n×R] R [n×T] T [n×R] R [n×T] T [n×R] R
[n×R] R [n×T] T [n×R] R [n×T] T [n×R] R [n×T] T

Good luck with the duration of the study and dropouts…

In general the intra-subject variability in steady state is substantially lower than after a single dose. If your drug is not nasty (extremely high CV) it might well be that you don’t need reference-scaling at all. I suggest to perform a pilot study to get an idea how the CV behaves.

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes
jag009
★★★

NJ,
2018-07-17 06:34

@ arl_stat
Posting: # 19074
Views: 1,132
 

 Multiple Dose, Steady State-Partial reference replicate

» Please help in understanding whether it is possible to conduct “An open-label, randomized, Multiple Dose, Steady State, two treatments, three periods, three sequence, three way, Reference Replicated crossover bioequivalence study” for USFDA Submission?

Why you are doing multiple dose? FDA does not like multiple dose (unless you are doing b2).

J
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
19,404 posts in 4,122 threads, 1,323 registered users;
online 19 (1 registered, 18 guests [including 5 identified bots]).
Forum time (Europe/Vienna): 18:42 CEST

No rational argument will have a rational effect on a man
who does not want to adopt a rational attitude.    Karl R. Popper

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5